Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842666 | 0.99 | ACHE (0.42) | ACHEP2RX7HTR1ADRD3DRD2 | |
| Lithium SCHEMBL1843522 | 0.99 | ACHE (0.42) | ACHEP2RX7HTR1ADRD3DRD2 | |
| SCHEMBL1842060 | 0.93 | TNF (0.37) | ACHEP2RX7ABL1NPC1RAB9A | |
| Lithium Ion SCHEMBL1843507 | 0.92 | ACHE (0.41) | ACHEP2RX7HTR1ADRD3DRD2 | |
| SCHEMBL1849172 | 0.92 | TNF (0.37) | ACHEP2RX7ABL1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1843304 | 0.91 | ACHE (0.40) | ACHEP2RX7HTR1ADRD3HTR2A | |
| Lithium Ion SCHEMBL1842051 | 0.89 | ACHE (0.36) | ACHEP2RX7ABL1NPC1RAB9A | |
| SCHEMBL2180521 | 0.87 | KDM4E (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1843018 | 0.87 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1842053 | 0.86 | ABL1 (0.35) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
| EP-2321309-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156966-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | ACHE 17/4885P2RX7 1791/4885HTR1A 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.